FORM 4
[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response...
0.5                       
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

SOMERS KIRK
2. Issuer Name and Ticker or Trading Symbol

Cardlytics, Inc. [ CDLX ]
5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director                    _____ 10% Owner
__X__ Officer (give title below)    _____ Other (specify below)
Chief Legal & Privacy Officer
(Last)          (First)          (Middle)

C/O CARDLYTICS, INC., 675 PONCE DE LEON AVENUE NE, SUITE 6000
3. Date of Earliest Transaction (MM/DD/YYYY)

10/21/2019
(Street)

ATLANTA, GA 30308
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
6. Individual or Joint/Group Filing (Check Applicable Line)

_X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock  10/21/2019    S(1)    1500  D $38.15  43283  D   

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares

Explanation of Responses:
(1)  These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 16, 2019.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
SOMERS KIRK
C/O CARDLYTICS, INC.
675 PONCE DE LEON AVENUE NE, SUITE 6000
ATLANTA, GA 30308


Chief Legal & Privacy Officer

Signatures
/s/ Kirk L. Somers 10/21/2019
**Signature of Reporting Person Date


Cardlytics (NASDAQ:CDLX)
Historical Stock Chart
From Apr 2024 to May 2024 Click Here for more Cardlytics Charts.
Cardlytics (NASDAQ:CDLX)
Historical Stock Chart
From May 2023 to May 2024 Click Here for more Cardlytics Charts.

Cardlytics, Inc. News

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
Cardlytics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Friday 3 May 2024 (1 day ago) • GlobeNewswire Inc.
Cardlytics Announces Timing of Its First Quarter 2024 Earnings Release
Thursday 25 April 2024 (1 week ago) • GlobeNewswire Inc.
Liane Hornsey Appointed to Cardlytics Board of Directors
Wednesday 10 April 2024 (3 weeks ago) • GlobeNewswire Inc.
Cardlytics Prices $150.0 Million Convertible Senior Notes Offering
Wednesday 27 March 2024 (1 month ago) • GlobeNewswire Inc.
Cardlytics Announces Proposed Convertible Senior Notes Offering
Tuesday 26 March 2024 (1 month ago) • GlobeNewswire Inc.
Adobe Stock Drops Following Below-Estimate Projections, Cardlytics Surges with Unexpected Profit, and More News
Friday 15 March 2024 (2 months ago) • IH Market News
Cardlytics Announces Fourth Quarter and Full Year 2023 Financial Results
Friday 15 March 2024 (2 months ago) • GlobeNewswire Inc.
Cardlytics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Saturday 9 March 2024 (2 months ago) • GlobeNewswire Inc.
Form 4 - Statement of changes in beneficial ownership of securities
Wednesday 6 March 2024 (2 months ago) • Edgar (US Regulatory)
Form 144 - Report of proposed sale of securities
Tuesday 5 March 2024 (2 months ago) • Edgar (US Regulatory)
Cardlytics Announces Timing of Its Fourth Quarter and Full Year 2023 Financial Results Conference Call and Webcast
Friday 1 March 2024 (2 months ago) • GlobeNewswire Inc.
Form EFFECT - Notice of Effectiveness
Monday 12 February 2024 (3 months ago) • Edgar (US Regulatory)